Early intervention remains vital in the management of acute stroke. The goals of imaging techniques are to establish a diagnosis as early as possible and to obtain accurate information about the intracranial vasculature and brain perfusion to guide therapeutic decisionmaking. Magnetic resonance imaging (MRI) and contrast-enhanced magnetic resonance angiography (CE-MRA) are valuable techniques in the evaluation of acute stroke and can provide diagnostic information on the underlying pathophysiological changes. Gadolinium-based contrast agents (GBCAs) facilitate the diagnosis of ischaemic stroke by accentuating abnormal flow kinetics and the diagnosis of nonischaemic stroke by assisting in the detection and characterisation of intracranial aneurysms and arteriovenous malformations (AVMs). Contrast agents may also be employed in the characterisation of vascular atherosclerotic plaque. Gadobutrol (Gadovist ® , Gadavist ® ) is a high relaxivity contrast agent which combines an excellent safety profile and proven high efficacy. As the only high concentration contrast media it allows to inject at a small and compact bolus, which has a direct impact on the performance of MRA or perfusion MRI procedure.
The majority (85 %) of strokes are ischaemic: patients present with asymptomatic bruits, transient ischaemic attacks (TIA) or manifest neurological symptoms. A TIA is a transient neurological deficit lasting from a few seconds to a few hours. Reversible ischaemic neurological deficit (RINd) is often included within the category of stroke and is a neurological deficit that lasts longer than 24 hours but less than 3 days and results in complete recovery. Prolonged reversible ischaemic neurological deficits (PRINd) may last for up to 7 days.
Non-ischaemic or haemorrhagic stroke is associated with higher mortality rates than ischaemic stroke. 2 Patients present with intracerebral or subarachnoid haemorrhage, causes of which include hypertension, intracranial aneurysms, arteriovenous malformations (AVMs), dural arteriovenous fistulas (dAVF), or cerebral amyloid angiopathy.
The first stage in the evaluation of patients with acute stroke is to elucidate the nature and aetiology of stroke (haemorrhage or infarction), identify infarcted and threatened tissue and visualise thrombi (see Table   1 ). 3 Neurovascular imaging techniques can assess these parameters within minutes of the patient arriving at the hospital and allow accurate diagnosis, prompt initiation of appropriate treatment, characterisation of disease progression and monitoring of the response to interventions.
Computed tomography (CT) has traditionally been the mainstay of imaging patients with acute stroke but its sensitivity for early infarction is less than ideal and it cannot accurately define the infarct core. It is also subject to substantial inter-rater variability in interpretation and magnetic resonance imaging (MRI) has demonstrated superiority for detection of acute intracranial haemorrhage. 4, 5 Traditionally, to obtain vascular and perfusion information with CT, multiple injections have been required although newer techniques have enabled the simultaneous acquisition of CT-perfusion and CT-angiography. 6 MRI techniques are becoming increasingly used in the diagnosis of stroke and enable identification of the infarct core and the relationship to the typically larger volume of ischaemic tissue (penumbra) (see Figure 1 ).
Magnetic Resonance Imaging of Stroke
A number of MRI techniques are used in stroke diagnosis. These are defined in Table 2 . The imaging regimen in acute stroke includes diffusion weighted imaging (dWI), T2 and fluid attenuated inversion recovery (FLAIR) weighted imaging, gradient recalled echo imaging (GRE) or susceptibilityweighted imaging (SWI) and magnetic resonance angiography (MRA), followed by physiological assessment with perfusion weighted imaging (PWI). 7 Stroke evaluation protocols should include a combination of dWI and PWI, because together they define the location and extent of ischaemia and infarction within minutes of onset. In addition, when performed in series, they can provide information about the pattern of evolution of the ischaemic lesion and treatment monitoring. Perfusion imaging can play an important role in identifying haemodynamic insufficiency and in grading its severity, and can be readily integrated into neuroimaging protocols. 9 Contrast-based PWI, also known as dynamic susceptibility contrast magnetic resonance perfusion (dSC-MRP) is based on a magnetic susceptibility contrast phenomenon involving T2 and T2*-effects of intravenous (iv) bolus-injected contrast agents. Images are acquired by serial imaging of the whole brain as a bolus of gadolinium-based contrast agent (GBCA) passes through the tissue capillary bed. From these images it is possible to calculate functional parameters such as relative cerebral blood flow (rCBF), relative cerebral blood volume (rCBV) and transit parameters including the mean transit time (MTT), time-to-maximum (Tmax) and time-to-peak (TTP) maps.
Complete interruption of blood flow in acute stroke results in irreversible injury within minutes. 10 In many cases, however, vascular occlusion by atherosclerotic plaques develops over time, which allows the development of a collateral blood supply to the affected tissues and this can sustain brain tissue for hours after the occlusion of major arteries to the brain. Cerebral tissue that is viable but at risk for infarction, the ischaemic penumbra, can be saved if appropriate intervention is promptly initiated. 8 The viability of this region may extend to 48 hours after the onset of stroke. Even in acute stroke, PWI can capture and characterise blood flow changes in the critical hours after symptom onset, allowing the opportunity assess the ischaemic penumbra and to intervene. determining the volume of the ischaemic penumbra helps to identify patients who would benefit from thrombolytic therapy or conventional treatments, such as carotid endarterectomy or blood pressure elevation.
The diffusion-perfusion mismatch, i.e. the difference in size between lesions captured by dWI and PWI, may also be used to assess the ischaemic penumbra and is a strong predictor of lesion volume growth.
It can measure the tissue at risk and has been increasingly used in the evaluation of hyperacute and acute stroke. 11, 12 Two clinical trials involving acute ischaemic stroke patients, (dEFUSE (n=74) and EPITHET (n=101), have established that a mismatch between PWI and dWI imaging volumes may be used to select patients for reperfusion treatment (see Figure 2) . 13, 14, 15 Infarct core is assessed by dWI, which has been found to have substantially better sensitivity and accuracy than CT in the assessment of hyperacute ischaemia. 4, 16 It is widely accepted that lesions with diffusion slowing represent tissues prone to infarction. After acute stroke, damage to the blood-brain barrier occurs 17 and allows leakage of contrast agent into cells from the extracellular space. However, increased use of dWI in acute stroke has revealed that lesions that initially show diffusion slowing may undergo diffusion normalisation.
It has therefore been concluded that acute slowing of diffusion is not necessarily an indicator of infarct.
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There is a need for a consensus on which perfusion measurement and processing methods should be routinely used in clinical practice. 19, 20 dSC-MRP in combination with dWI is most commonly used in the evaluation of acute stroke and TIAs. intracranial vasculature. Several different MRA techniques may be used for imaging cerebral vessels, including 3d ToF and contrast-enhanced MRA (CE-MRA). 24 CE-MRA is increasingly specified in standard protocols for the diagnosis of acute stroke. In a study (n=66) comparing ToF-MRA and CE-MRA, the latter enabled superior visualisation of vessels distal to the occlusion. Furthermore CE-MRA allowed visualisation of extracranial vessels and faster image acquisition. 25 CE-MRA can also be used to Some are benign and require no treatment. However, other malformations such as arteriovenous malformation (AVM) and arteriovenous fistulas (AVF) may result in haemorrhagic stroke. CE-MRA has been increasingly used for the diagnosis and characterisation of these malformations and gives the detailed images of their location, feeding vessels and drainage patterns.
Three-dimensional time-of-flight (ToF) CE-MRA has become an established non-invasive imaging tool in the evaluation of atherosclerotic pathology of carotid arteries 28, 29, 30 and provides better image quality, greater diagnostic confidence and more inter-observer agreement compared with 2d ToF MRA. 31 It has also proven a useful supplement to digital subtraction angiography (dSA). The technique shows high sensitivity and specificity at detecting disease not only in the carotid vessels, but also in the vertebrobasilar circulation, and has the potential to provide a comprehensive and non-invasive evaluation of the head and neck arteries in a single study. however, CE-MRA has high sensitivity and specificity in the assessment and grading of AVMs. 33, 34 Two recent studies comparing dSA and 4d dynamic MR Angiography (4d-MRA) have confirmed that the latter is a promising technique in the diagnosis and follow-up of cerebral AVMs, providing functional information that has until recently been gained only with dSA. 35, 36 In both studies, classification by 4d-MRA and dSA matched in all patients. An example of the visualisation of AVM using CE-MRA is given in Figure 3 .
CE-MRA is useful in the evaluation of intracranial aneurysms treated with detachable coils. However, aneurysm recanalisation may occur because of coil compaction or regrowth of a residual neck and therefore follow-up imaging of these structures is important. Such imaging has historically involved repeated intra-arterial cerebral catheter angiography, an invasive procedure with associated risks.
MRA provides a noninvasive alternative with less discomfort and morbidity for patients. A retrospective study (n=232), in which patients underwent CE-MRA and dSA for depiction of aneurysmal remnants of coiled cerebral aneurysms, showed that CE-MRA was at least equivalent to dSA. In addition, contrast filling within the coil mass was more clearly seen with CE-MRA than with dSA. 37 A recent study has also shown that CE-MRA is an accurate technique for follow-up of aneurysms following stent-assisted coiling with excellent depiction of remnants in spite of the presence of a stent. 38 An example of the use of CE-MRA in a patient with turbulent flow basilar aneurysm is given in 
Use of Gadolinium-based Contrast Agents in Neurovascular Imaging
The first GBCA became commercially available in 1988 and many GBCAs are now approved for use in neurovascular MRI; a summary of commercially available agents is given in Table 3 . Typically, gadolinium (Gd) agents are extracellular, non-tissue-specific, non-protein-binding, water-soluble compounds. The Gd3+ ion has strong magnetic properties, which causes a T1-relaxation shortening of protons and the production of a high signal in T1-weighted MR sequences. 40 The structure of GBCAs is either a linear or macrocyclic chelate and they are available as ionic or non-ionic preparations. The molecular structure and ionicity determines the stability of GBCAs. 41 Linear chelates are flexible open chains that do not offer a strong binding to Gd3+ ions. Macrocyclic chelates, however, bind strongly to Gd3+ ions as they comprise rigid rings which cage the gadolinium atom, and therefore significantly reduce the level of free Gd3+ions after application. Non-ionic linear molecules are also less stable compared with ionic ones: the binding between Gd3+ ions and negatively charged carboxyl groups is stronger than that with amides or alcohol in the non-ionic preparations. 42 The ability of GBCAs to bind Gd3+ ions has important safety implications. Some GBCAs have been associated with adverse effects resulting from the release of Gd3+ ions in vivo. These include an increased risk of nephrogenic systemic fibrosis (NSF), a rare disorder that principally affects the skin but may affect other organs, in patients with renal insufficiency. [43] [44] [45] [46] [47] [48] Agents carrying higher risk for NSF are contraindicated for use in patients with acute kidney injury or chronic
Figure 2: Comparison of Perfusion Imaging and Routine Imaging
Routine imaging shows a small infarction within the left middle cerebral artery territory. Gadobutrol was the contrast medium used.
Perfusion imaging with dynamic susceptibility contrast-time to peak (DSC-TTP) and arterial spin labelling-cerebral blood flow (ASL-CBF) reveals ischaemia within the entire middle cerebral artery territory with a large mismatch with the small area of infarction.
Gadobutrol was the contrast medium used.
severe kidney disease. These agents include gadodiamide (omniscan ® ), gadopentetate dimeglumine (Magnevist ® ) and gadoversetamide (optiMARK ® ) (see Table 3 ). Agents in the lower-risk category must still carry warning labels, but they do not require contraindications.
These include gadoteridol (ProHance ® ), gadoterate (dotarem ® ) and gadobutrol (Gadovist ® ). produces a significantly smaller bolus width at half maximum signal intensity decrease, a smaller mean peak time, a higher contrast and contrast-to-noise ratio (CNR) between grey and white matter. 54 This is advantageous for PWI as image quality is dependent on the geometry of the contrast bolus, which in turn is optimised by an increased concentration of the injected contrast solution in brain tissues. 9, 55 Gadobutrol leads to shortening of the relaxation times even in low concentrations. In healthy volunteers, 1.0 mol/L gadobutrol administered Gadobutrol was the contrast medium used.
at a dose of 0.3 mmol/kg body weight (bw) yielded MR perfusion images that were superior to those obtained with the 0.5 mol/L formulation. 54 The standard dose currently used is 0.1 mmol/kg bw.
Gadobutrol is well tolerated and has a good safety profile. In a review of 14,299 patients receiving iv injection of gadobutrol in routine clinical radiology practices, the percentage of patients reporting at least one adverse drug reaction (AdR) was low (0.55 %). Two (0.01 %) serious AdRs were reported. The most frequently reported AdR was nausea, which occurred in 0.25 % of patients. The observed occurrence of AdRs was similar to published safety data of other Gd-based contrast agents.
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Clinical Studies of Gadobutrol in Neurovascular Imaging
Gadobutrol in Magnetic Resonance Imaging
The first study of gadobutrol in stroke evaluated its efficacy and safety in the assessment of cerebral haemodynamics by dSC-MRP.
The multicentre double-blinded study involved patients (n=89) with carotid artery stenosis or cerebral infarcts and used dosages from 0.1 to 0.5 mmol/kg bw. The dose of 0.3 mmol/kg bw was found to be diagnostically adequate. gadobutrol was safe and well-tolerated.
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A randomised intraindividual study (n=12) found that gadobutrol was equivalent to gadobenate dimeglumine for cerebral PWI at 1.5T . The In a comparison of gadopentetate dimeglumine and gadobutrol in the evaluation of 56 patients with cerebral AVMs using 4d MRA, vessel sharpness and diameter did not differ substantially between the two groups. However, vessel-to-background contrast was significantly higher in the gadobutrol group (p<0.005).
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Summary and Conclusion
Neuroimaging in acute stroke is essential for establishment of an accurate diagnosis and monitoring of the response to interventions.
Magnetic resonance techniques including MRI and MRA have higher accuracy, fewer safety risks and provide a greater range of diagnostic information than CT and can provide a definitive diagnosis within minutes of a patient's arrival to the hospital. The utility of MR imaging in acute stroke management lies not only in its capability to detect early ischaemic lesions with high sensitivity, but also in its capacity to reveal specific features of cerebrovascular pathology. The role of
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EURoPEAN NEURoLoGICAL REVIEW MRI in acute stroke management is an area of active research.
Results from MRI-based clinical trials are helping to refine the mismatch concept and penumbral imaging is a promising technique that will enable the identification of individuals who might benefit from thrombolytic treatment beyond the current therapeutic window.
These advances may result in improvements in patient outcomes and cost-effectiveness.
Contrast agents have greatly enhanced the utility of MR techniques.
Gadobutrol is the only 1 M contrast medium currently available and has an excellent safety profile. Its concentrated formulation and high relaxivity, result in superior bolus characteristics and enhancement allowing improved diagnostic efficacy in PWI and CE-MRA. The use of new high-relaxivity contrast agents is critical when defining more appropriate and effective therapeutic management approaches. n
